title: Facilitation of receptive behavior in estrogen-primed female rats by the anti-progestin, RU 486.
abstract: The progestin receptor antagonist RU 38486 (henceforth referred to as RU 486) was tested for facilitative effects on female receptive behavior in ovariectomized Long-Evans rats primed with 2 micrograms estradiol benzoate (EB). RU 486 (0, 0.5, 1.6, or 5.0 mg) was administered 48 hr after estrogen priming. The lordosis quotient (LQ) and lordosis score (LS) were assessed 4 hr after RU 486 administration in a standardized test consisting of a 10-mount test by a stimulus male. A significant dose effect was found by both LQ and LS, with those subjects receiving 5 mg of RU 486 being significantly more receptive than vehicle control animals. Thus RU 486 acted as a weak progestin agonist under testing conditions typical for assessment of progestin facilitation of female sexual behavior in rats. Low levels of proceptive behavior (hops and darts) were seen in a minority of the tests, and did not vary systematically as a function of the dose of RU 486 administered. We also examined the effects of RU 486 given before progesterone (P) on receptivity in a blocking paradigm and confirmed previous reports that the antagonist significantly attenuates facilitation of sexual behavior when given in combination with P. A progestin receptor assay of the cytosols of the hypothalamus-preoptic area in estrogen-primed female rats treated with 5 mg RU 486 revealed a significantly greater depletion of available cytosolic P receptors than when rats were treated with a similarly facilitating dose of P (100 micrograms). The results suggest a possible dual mode of action for RU 486--a weak, receptor-mediated agonistic effect on sexual behavior when given alone to estrogen-primed rats, and a competitive blocking effect on receptivity when administered with P.
authors.affiliation: Department of Biological Sciences, Rutgers College, Rutgers University, Piscataway, New Jersey 08855-1059.
authors.forename: E T
authors.initials: ET
authors.lastname: Pleim
authors.forename: P J
authors.initials: PJ
authors.lastname: Cailliau
authors.forename: M A
authors.initials: MA
authors.lastname: Weinstein
authors.forename: A M
authors.initials: AM
authors.lastname: Etgen
authors.forename: R J
authors.initials: RJ
authors.lastname: Barfield
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D007279:Injections, Subcutaneous; D015735:Mifepristone / Q000494:pharmacology*; D051381:Rats; D011960:Receptors, Estrogen / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects; D012726:Sexual Behavior, Animal / Q000187:drug effects*
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D015735:Mifepristone; D004958:Estradiol